Traws Pharma, Inc. Logo

Traws Pharma, Inc.

Develops oral small-molecule therapies for respiratory viral diseases and cancer.

TRAW | US

Overview

Corporate Details

ISIN(s):
US68232V8845 (+1 more)
LEI:
Country:
United States of America
Address:
12 PENNS TRAIL, 18940 NEWTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company that develops novel, oral small-molecule therapies for respiratory viral diseases and cancer. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Its pipeline includes Ratutrelvir, a ritonavir-independent treatment targeting the main protease (Mpro) for COVID-19 and Long COVID, and Tivoxavir marboxil, a single-dose therapy targeting the cap-dependent endonuclease (CEN) for bird flu and seasonal influenza. Traws Pharma aims to develop safe product candidates with simple dosing regimens and utilizes accelerated clinical trial strategies for vulnerable patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Traws Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Traws Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Traws Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SELLAS Life Sciences Group, Inc. Logo
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
United States of America
SLS
Sensei Biotherapeutics, Inc. Logo
Developing tumor-activated biologics to stimulate a targeted immune response against cancer.
United States of America
SNSE
Senti Biosciences, Inc. Logo
Developing smart cell and gene therapies with Gene Circuits to precisely target cancer.
United States of America
SNTI
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea
018680
Septerna, Inc. Logo
Advancing novel small molecule GPCR medicines for endocrine, immune, and metabolic diseases.
United States of America
SEPN
SERA PROGNOSTICS, INC. Logo
Develops predictive blood tests to assess preterm birth risk and improve pregnancy outcomes.
United States of America
SERA
Seres Therapeutics, Inc. Logo
Developing live biotherapeutics from the microbiome to treat infections and immune diseases.
United States of America
MCRB
Serina Therapeutics, Inc. Logo
Developing safer, more effective drugs for neurology and cancer using polymer technology.
United States of America
SER
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye
SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea
378800

Talk to a Data Expert

Have a question? We'll get back to you promptly.